NGM Biopharmaceuticals wants to be the next billion-dollar biotech on Wall Street, and so it’s moving forward with an IPO that offers a springtime referendum on investor sentiment.
Back in September, South San Francisco-based NGM filed paperwork to go public but fell silent as biotech indices tumbled in the fourth quarter. Now, apparently pleased with the state of the market, NGM has revived those plans and is pitching an offering that would value the company at about $1.1 billion.
About the Author Reprints
